SAMIRNA
LIVE

Serial Number

86287682

Owner

Bioneer Corporation

Attorney

Jun-Hwa Jeong

Filing Date

May 21, 2014

Add to watchlist:

No watchlists yet
View on USPTO

SAMIRNA Trademark

Serial Number: 86287682 • Registration: 5052167

SAMIRNA is a trademark filed by Bioneer Corporation on May 21, 2014. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Bioneer Corporation (23 trademarks)

8-11, Munpyeong Seo-ro, Daedeok-gu
Daejeon, 306-220 , KR

Entity Type: 03

Trademark Details

Filing Date

May 21, 2014

Registration Date

October 4, 2016

Published for Opposition

July 19, 2016

Goods & Services

Pharmaceutical preparations for the treatment of cancer, tumor, respiratory disease, immunization disease, skin disease, viral disease, allergies; Biological preparations for the treatment of cancer, tumor, respiratory disease, immunization disease, skin disease, viral disease, allergies; Medicated vaccines and serums for treatment of cancer, tumor, respiratory disease, immunization disease, skin disease, viral disease, allergies; Capsules sold empty for pharmaceutical purposes for the treatment of cancer, tumor, respiratory disease, immunization disease, skin disease, viral disease, allergies; Microspheres containing pharmaceutical preparations, for treating cancer, tumor, respiratory disease, immunization disease, skin disease, viral disease, allergies; Preparations and substances for facilitating delivery of pharmaceutical preparations, namely, drug delivery agent in the form of nanoparticle for transferring siRNA in the cell; Carriers for drug delivery, namely, drug delivery agent in the form of nanoparticle for transferring siRNA in the cell; Peptides for drug delivery, namely, drug delivery agents consisting of peptides attached to drugs that facilitate delivery of pharmaceutical preparations; Pharmaceutical preparations applied pharmaceutical drug delivery system, namely, elixirs for the treatment of cancer, tumor, respiratory disease, immunization disease, skin disease, viral disease, allergies and a nanoparticle carrier for transferring siRNA in the cell or peptide; Chemical reagents for medical use; Pharmaceutical preparations for drug delivery into cells; Drug delivery formulations, namely, compositions consisting of nanoparticle for transferring siRNA in the cell or peptides; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals for medical purpose; Pharmaceutical preparations and substances for facilitating drug delivery in the form of nanoparticle for transferring siRNA in the cell or peptide for use in medical treatment via inhibition of gene expression; Pharmaceutical preparations containing RNA for use in medical treatment via inhibition of gene expression; Pharmaceutical preparations containing DNA for use in medical treatment via inhibition of gene expression

Diagnostic preparations for research use; Reagents for scientific research use; Chemicals for laboratory analyses, other than for medical use, namely, chemicals for use in biotechnological product development; Chemicals for pharmaceutical purposes, namely, for use in the manufacture of drugs and medicines; Chemicals for the manufacture of medical products in the nature of pharmaceutical preparations; Biochemicals, namely, biochemical reagents used for non-medical purposes; Chemical preparations for the manufacture of medical products

[ Drug delivery system; Implantable drug syringes for drug delivery devices; Implantable drug delivery pumps for drug delivery devices; Medical apparatus for introducing pharmaceutical preparations into the human body; Medical apparatus for facilitating the inhalation of pharmaceutical preparations; Injection device for pharmaceuticals; Microspheres, namely, unilaminar and bilaminar spherical particles comprising hydrophilic and hydrophobic polymers with diameters in the nanometer range used as a means for drug delivery for treating cancer, tumor, respiratory disease, immunization disease, skin disease, viral disease, allergies ]

Pharmaceutical products research; Pharmaceutical products development; Research for medical products; Crude medicines research; Research and development of biotechnology for others; Quality control, namely, quality control of target gene expression activity with siRNA; Biotechnology research

Filing History

COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Oct 4, 2025 REM2
NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
Oct 5, 2022 NAS8
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED
Oct 5, 2022 8.PR
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Oct 4, 2022 APRE
TEAS SECTION 8 RECEIVED
Apr 26, 2022 ES8R
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Oct 4, 2021 REM1
REGISTERED-PRINCIPAL REGISTER
Oct 4, 2016 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 19, 2016 NPUB
PUBLISHED FOR OPPOSITION
Jul 19, 2016 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 29, 2016 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Jun 15, 2016 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 8, 2016 CNSA
EXAMINER'S AMENDMENT ENTERED
Jun 8, 2016 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jun 8, 2016 GNEN
EXAMINERS AMENDMENT E-MAILED
Jun 8, 2016 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jun 8, 2016 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
May 21, 2016 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 20, 2016 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 20, 2016 TROA
NOTIFICATION OF PRIORITY ACTION E-MAILED
Nov 23, 2015 GPRN
PRIORITY ACTION E-MAILED
Nov 23, 2015 GPRA
PRIORITY ACTION WRITTEN
Nov 23, 2015 CPRA
DATA MODIFICATION COMPLETED
Nov 16, 2015 DMCC
ASSIGNED TO LIE
Nov 16, 2015 ALIE
ASSIGNED TO EXAMINER
Nov 9, 2015 DOCK
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 23, 2015 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 23, 2015 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Oct 23, 2015 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Aug 21, 2015 GNS2
INQUIRY TO SUSPENSION E-MAILED
Aug 21, 2015 GNSI
SUSPENSION INQUIRY WRITTEN
Aug 21, 2015 CNSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Feb 6, 2015 GNS3
LETTER OF SUSPENSION E-MAILED
Feb 6, 2015 GNSL
SUSPENSION LETTER WRITTEN
Feb 6, 2015 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 5, 2015 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 4, 2015 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 4, 2015 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 4, 2014 GNRN
NON-FINAL ACTION E-MAILED
Aug 4, 2014 GNRT
NON-FINAL ACTION WRITTEN
Aug 4, 2014 CNRT
ASSIGNED TO EXAMINER
Aug 4, 2014 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 4, 2014 NWOS
NEW APPLICATION ENTERED
May 24, 2014 NWAP